Profil
Nicholas Malden is Chief Financial Officer, Secretary & Senior Vice President of Ventana Medical Systems, Inc. He joined Ventana in October 2000 and resigned as Senior Vice President, Chief Financial Officer, and Corporate Secretary during 2007.
From 1985 until joining Ventana, Mr. Malden was Vice President-Finance for the Duracell Global Business Management Group at Duracell International.
Mr. Malden received a BA in Political Science from the Grinnell College and an MBA from the Emory University.
Ehemalige bekannte Positionen von Nicholas Malden
| Unternehmen | Position | Ende |
|---|---|---|
Ventana Medical Systems, Inc.
 Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Finanzdirektor/CFO | 01.05.2007 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Electronic Technology |
